Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes

Aleksandra G&aogon;secka,1 Piotr Szwed,1 Karolina Jasi&nacute;ska,1 Oliwia Fidali,1 Aleksandra K&lstrok;&eogon;bukowska,1 Ceren Eyileten,2 Marek Postula,2 &Lstrok;ukasz Szarpak,3,4 Tomasz Mazurek,1 Grzegorz Opolski,1 Krzysztof J Filipiak,1 Marcin Ufnal5 1 1st Chair and Department...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gąsecka A, Szwed P, Jasińska K, Fidali O, Kłębukowska A, Eyileten C, Postula M, Szarpak Ł, Mazurek T, Opolski G, Filipiak KJ, Ufnal M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	nitric oxide l-arginine acute myocardial infarction major adverse cardiovascular events prognosis Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/2e5d2715bf7047f8b06aab171ed65a01
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e5d2715bf7047f8b06aab171ed65a01
record_format	dspace
spelling	oai:doaj.org-article:2e5d2715bf7047f8b06aab171ed65a012021-12-02T18:49:42ZSymmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes1178-7031https://doaj.org/article/2e5d2715bf7047f8b06aab171ed65a012021-08-01T00:00:00Zhttps://www.dovepress.com/symmetric-dimethylarginine-is-altered-in-patients-after-myocardial-inf-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Aleksandra G&aogon;secka,1 Piotr Szwed,1 Karolina Jasi&nacute;ska,1 Oliwia Fidali,1 Aleksandra K&lstrok;&eogon;bukowska,1 Ceren Eyileten,2 Marek Postula,2 &Lstrok;ukasz Szarpak,3,4 Tomasz Mazurek,1 Grzegorz Opolski,1 Krzysztof J Filipiak,1 Marcin Ufnal5 1 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, 02-097, Poland; 2Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-097, Poland; 3Bialystok Oncology Center, Bialystok, 15-027, Poland; 4Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, 03-411, Poland; 5Department of Experimental Physiology and Pathophysiology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-106, PolandCorrespondence: Aleksandra G&aogon;secka 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, Warsaw, 02-097, PolandTel +48 22 599 19 51Email aleksandra.gasecka@wum.edu.plPurpose: Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality worldwide. Damage to the endothelium is the earliest event in atherothrombosis, including AMI. Nitric oxide (NO), an endothelium-derived compound, protects the vasculature from damage. This study evaluated whether an association exists between plasma concentration of endogenous NO-related pathway metabolites linked to AMI and major adverse cardiovascular events (MACE) after AMI.Methods: We compared plasma concentrations of NO-related pathway metabolites in patients after AMI (n=60) and healthy controls (n=27) and investigated the prognostic value of these metabolites for post-AMI MACE development over a median of 3.5-years. In search of biomarkers, we compared plasma concentrations of dimethylarginines (ADMA, SDMA), citrulline, arginine and ornithine using ultra performance liquid chromatograph coupled with a mass spectrometer.Results: Patients after AMI had higher concentrations of dimethylarginines, compared to controls (p=0.0068, p< 0.0001, respectively). Conversely, the concentration of citrulline was lower in the AMI group (p=0.0006). The concentration of SDMA was higher in patients who developed MACE than in those who did not (p=0.015). SDMA was the only independent predictor of MACE in multivariate analysis (p=0.023). There was an intermediate, negative correlation between plasma SDMA level and platelet reactivity (r=− 0.33, p=0.02).Conclusion: Plasma concentration of dimethylarginines differs between patients with AMI and healthy volunteers. The study’s novel finding is that SDMA is an independent predictor of MACE during a 3.5 year follow-up period after AMI.Keywords: nitric oxide, L-arginine, acute myocardial infarction, major adverse cardiovascular events, prognosisGąsecka ASzwed PJasińska KFidali OKłębukowska AEyileten CPostula MSzarpak ŁMazurek TOpolski GFilipiak KJUfnal MDove Medical Pressarticlenitric oxidel-arginineacute myocardial infarctionmajor adverse cardiovascular eventsprognosisPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3797-3808 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	nitric oxide l-arginine acute myocardial infarction major adverse cardiovascular events prognosis Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	nitric oxide l-arginine acute myocardial infarction major adverse cardiovascular events prognosis Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Gąsecka A Szwed P Jasińska K Fidali O Kłębukowska A Eyileten C Postula M Szarpak Ł Mazurek T Opolski G Filipiak KJ Ufnal M Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
description	Aleksandra G&aogon;secka,1 Piotr Szwed,1 Karolina Jasi&nacute;ska,1 Oliwia Fidali,1 Aleksandra K&lstrok;&eogon;bukowska,1 Ceren Eyileten,2 Marek Postula,2 &Lstrok;ukasz Szarpak,3,4 Tomasz Mazurek,1 Grzegorz Opolski,1 Krzysztof J Filipiak,1 Marcin Ufnal5 1 1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, 02-097, Poland; 2Department of Experimental and Clinical Pharmacology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-097, Poland; 3Bialystok Oncology Center, Bialystok, 15-027, Poland; 4Maria Sklodowska-Curie Medical Academy in Warsaw, Warsaw, 03-411, Poland; 5Department of Experimental Physiology and Pathophysiology, Centre for Preclinical Research and Technology, Medical University of Warsaw, Warsaw, 02-106, PolandCorrespondence: Aleksandra G&aogon;secka 1st Chair and Department of Cardiology, Medical University of Warsaw, Banacha 1a, Warsaw, 02-097, PolandTel +48 22 599 19 51Email aleksandra.gasecka@wum.edu.plPurpose: Acute myocardial infarction (AMI) is the leading cause of morbidity and mortality worldwide. Damage to the endothelium is the earliest event in atherothrombosis, including AMI. Nitric oxide (NO), an endothelium-derived compound, protects the vasculature from damage. This study evaluated whether an association exists between plasma concentration of endogenous NO-related pathway metabolites linked to AMI and major adverse cardiovascular events (MACE) after AMI.Methods: We compared plasma concentrations of NO-related pathway metabolites in patients after AMI (n=60) and healthy controls (n=27) and investigated the prognostic value of these metabolites for post-AMI MACE development over a median of 3.5-years. In search of biomarkers, we compared plasma concentrations of dimethylarginines (ADMA, SDMA), citrulline, arginine and ornithine using ultra performance liquid chromatograph coupled with a mass spectrometer.Results: Patients after AMI had higher concentrations of dimethylarginines, compared to controls (p=0.0068, p< 0.0001, respectively). Conversely, the concentration of citrulline was lower in the AMI group (p=0.0006). The concentration of SDMA was higher in patients who developed MACE than in those who did not (p=0.015). SDMA was the only independent predictor of MACE in multivariate analysis (p=0.023). There was an intermediate, negative correlation between plasma SDMA level and platelet reactivity (r=− 0.33, p=0.02).Conclusion: Plasma concentration of dimethylarginines differs between patients with AMI and healthy volunteers. The study’s novel finding is that SDMA is an independent predictor of MACE during a 3.5 year follow-up period after AMI.Keywords: nitric oxide, L-arginine, acute myocardial infarction, major adverse cardiovascular events, prognosis
format	article
author	Gąsecka A Szwed P Jasińska K Fidali O Kłębukowska A Eyileten C Postula M Szarpak Ł Mazurek T Opolski G Filipiak KJ Ufnal M
author_facet	Gąsecka A Szwed P Jasińska K Fidali O Kłębukowska A Eyileten C Postula M Szarpak Ł Mazurek T Opolski G Filipiak KJ Ufnal M
author_sort	Gąsecka A
title	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
title_short	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
title_full	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
title_fullStr	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
title_full_unstemmed	Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes
title_sort	symmetric dimethylarginine is altered in patients after myocardial infarction and predicts adverse outcomes
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/2e5d2715bf7047f8b06aab171ed65a01
work_keys_str_mv	AT gaseckaa symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT szwedp symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT jasinskak symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT fidalio symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT kłebukowskaa symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT eyiletenc symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT postulam symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT szarpakł symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT mazurekt symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT opolskig symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT filipiakkj symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes AT ufnalm symmetricdimethylarginineisalteredinpatientsaftermyocardialinfarctionandpredictsadverseoutcomes
_version_	1718377551595831296

Symmetric Dimethylarginine is Altered in Patients After Myocardial Infarction and Predicts Adverse Outcomes

Ejemplares similares